EDITAS MEDICINE, INC. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
EDITAS MEDICINE, INC. (EDIT) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $2.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-04.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2024-11-04
- 2024-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $2.00K.
- 2024-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $40.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2024-09-30 | $2.00K 10-Q · filed 2024-11-04 |
| 2024-06-30 | $40.00K 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |